<DOC>
	<DOCNO>NCT02970773</DOCNO>
	<brief_summary>The primary objective study investigate pharmacokinetic -dynamic property rivaroxaban oral administration cervical spinal cord injury ( SCI ) individual . The secondary objective study determine steady-state rivaroxaban activity cervical SCI individual long-term therapy . Primary Objective In-house patient inform concern study inform consent collect . During screen day , in- / exclusion criterion assess blood sample take assess haematology , clinical chemistry coagulation parameter . Furthermore , evaluation day schedule . On evaluation day , in- / exclusion criterion re-assessed . A venous catheter introduce forearm low leg participant collection blood specify time point . Skin inspection subcutaneous bleeding perform vital sign record . A blood sample take assess haematology , clinical chemistry coagulation parameter . Single administration oral rivaroxaban form XareltoÂ® 10mg tablet ( Bayer Schering Pharma , Berlin , Germany ) . Rivaroxaban concentration determine plasma sample take , 30min 1 , 2 , 3 , 4 , 5 , 6 , 8 , 12 , 24 hour rivaroxaban administration . Rivaroxaban activity determine plasma sample take , 30min 1 , 2 , 3 , 4 , 5 , 6 , 8 , 12 , 24 hour rivaroxaban administration use factor Xa inhibition test measure prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) . Skin inspection subcutaneous bleeding measurement vital sign perform 30min 1 , 2 , 3 , 4 , 5 , 6 , 8 , 12 24 hour rivaroxaban administration . Secondary Objective Patients long-term rivaroxaban therapy recruit annual check-up visit Swiss Paraplegic Centre . In- / exclusion criterion assess , patient inform concern study inform consent collect . Blood sample take assess haematology , clinical chemistry coagulation parameter , skin inspection subcutaneous bleeding measurement vital sign perform . A blood sample ( 4.3ml citrate venous blood ) take assess primary secondary outcome parameter .</brief_summary>
	<brief_title>Absorption Rivaroxaban Patients With Cervical Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Motor complete tetraplegia least 3 month Age 18 74 year Body mass index ( BMI ) 18 35kg/m2 Informed consent document signature Any anticoagulation therapy ( apart rivaroxaban second objective ) Hypersensitivity allergy factor Xa inhibitor Acute bacterial endocarditis Bleeding disorder Clinically relevant active bleed Gastrointestinal ulcer tumor Hepatic dysfunction increase bleed risk Renal failure / patient undergoing dialysis Pregnancy breast feed Gastrectomy , biliopancreatic diversion , resection rerouting small intestine Feeding tube Recent blood donation Abnormalities laboratory value : alanineaminotransferase ( ALAT ) , aspartateaminotransferase ( ASAT ) , gammaglutamyl transferase ( gammaGT ) , alkalic phosphatase ( AP ) , bilirubin , amylase , lipase , cystatin C , creatinine , white blood cell count , haemoglobin , platelet count , prothrombin time , aPTT , fibrinogen , thrombin time , factor II , V , VII X Use therapeutic recreational drug influence plasmatic coagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>